MARKET

MDWD

MDWD

Mediwound
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.000
+0.010
+0.33%
Closed 16:00 12/11 EST
OPEN
3.050
PREV CLOSE
2.990
HIGH
3.050
LOW
2.920
VOLUME
64.70K
TURNOVER
--
52 WEEK HIGH
6.09
52 WEEK LOW
2.548
MARKET CAP
81.54M
P/E (TTM)
7.04
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MDWD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MDWD News

  • Edited Transcript of MDWD earnings conference call or presentation 14-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.6d ago
  • MediWound launches mid-stage study of EscharEx in venous leg ulcers
  • Seeking Alpha - Article.12/03 17:37
  • MediWound Initiates U.S. Phase 2 Adaptive Design Study of EscharEx® for Treatment of Venous Leg Ulcers
  • GlobeNewswire.12/03 12:30
  • MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/14 19:27

More

Industry

Pharmaceuticals
+0.17%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About MDWD

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
More

Webull offers Mediwound Ltd (MDWD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.